A new study from Spain has brought encouraging news in the fight against pancreatic cancer, one of the most aggressive and difficult cancers to treat. Researchers say the findings are promising, although they also stress that the work is still in an early stage and has not yet been tested in humans.

According to research published in PNAS, scientists studied pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer. In mouse models, a three-drug combination led to strong and lasting tumor regression, and reports from the research team say the response remained durable for around 200 days in these experimental settings. The treatment was also described as well tolerated in mice, without significant toxicities being observed in the study.

The research was led by Professor Mariano Barbacid and his team at the Spanish National Cancer Research Centre, also known as CNIO. The study focused on a targeted therapy strategy designed to block key pathways that help pancreatic tumors survive and develop resistance to treatment.

What makes the findings especially important is that pancreatic cancer has long been known for quickly becoming resistant to treatment. In this study, the triple-drug approach appeared to delay or prevent that resistance in the animal models used, which is one reason the results have attracted so much attention.

Still, researchers have been clear that this is not yet a cure for people. The results are preclinical, meaning they come from laboratory and animal research rather than human trials. More studies are still needed before this therapy can be considered for patients, and experts caution that treatments that work in mice do not always prove successful in humans.

Even so, the study is being viewed as an important step forward. It suggests that carefully designed combination therapies may eventually improve how pancreatic cancer is treated in the future. For now, the findings represent a major research milestone rather than a finished medical solution.